Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Measurement of serum miR-455-5p level
Timeframe: the miR-455-5p level is collected at week 0, 6, 12 and 24.
Measurement of LVPWd and LVPWs
Timeframe: the LVPWd and LVPWs are collected at week 0, 6, 12 and 24.
Measurement of LVIDd and LVIDs
Timeframe: the LVIDd and LVIDs are collected at week 0, 6, 12 and 24.
Measurement of IVSTd and IVSTs
Timeframe: the IVSTd and IVSTs are collected at week 0, 6, 12 and 24.
Calculation of LVMi
Timeframe: the LVMi is calculated at week 0, 6, 12 and 24.
Measurement of LVEF
Timeframe: the EF is calculated at week 0, 6, 12 and 24.
Measurement of FS
Timeframe: the FS is calculated at week 0, 6, 12 and 24.
SBP
Timeframe: the SBP is collected at week 0, 6, 12 and 24.
DBP
Timeframe: the DBP is collected at week 0, 6, 12 and 24.